Caligor’s services are used to manage the regulatory, logistics and supply chain challenges of sourcing, storing and distributing investigational drugs used in comparator clinical trials (a comparator trial compares an experimental drug to a drug that is already being used to treat patients) and unlicensed medicines for expanded access programs (programs for patients who have life-threatening conditions but lack access to clinical trials or approved therapeutic alternatives). The company was founded in 1919 and is headquartered in Secaucus, NJ with an additional facility just east of London in Dartford, UK (www.caligorrx.com).
“Caligor has a strong, successful track record of delivering strategic clinical trial supply and logistics services to the pharmaceutical and biotechnology industries,” said Kevin Ma, a managing director for Diversis Capital.
Diversis plans to invest heavily in Caligor to build its sales and marketing, logistics capabilities, distribution infrastructure and service offerings. These investments include a new warehouse in Dartford, UK that will have about five times more space than the current UK facility. “We will provide additional resources and operational expertise to expand the company’s comparator and global access programs, broaden the reach of its businesses to new geographic regions, enhance its logistics capabilities and build on its leadership position,” said Mr. Ma.
Diversis Capital makes control investments in lower and middle market companies that have at least $20 million of revenue and up to $20 million of EBITDA. Transaction types include carve-outs, standalone transactions and special situations. Sectors of interest include technology, telecom, healthcare, industrials, consumer, and government and business services. The firm was founded in 2013 by managing directors Ron Nayot and Kevin Ma along with Marc Luzzatto, the firm’s Chairman. Diversis is based in Santa Monica (www.diversiscapital.com).
Tammy Bishop, managing director of Caligor, has been named Caligor’s new CEO following the acquisition of the company by Diversis.
© 2016 Private Equity Professional • Private Equity’s Leading News Magazine • 4-11-16